CPEX Pharmaceuticals completes enrollment in Nasulin Stage 2a clinical trial CPEX Pharmaceuticals, Inc. The scholarly study was initiated in February of this year and randomized 94 subjects. Results are expected at the ultimate end of the first one fourth or start of the second quarter of 2010. The Stage 2a, double-blind, placebo-managed trial has been conducted at multiple centers over the U.S. Efficacy, as measured by the proportion of time spent with normal sugar levels, or euglycemia, is being assessed using constant glucose monitoring.announced today that the European Commission provides granted advertising approval for 3,4-diaminopyridine , for the uncommon autoimmune disease Lambert Eaton Myasthenic Syndrome . Amifampridine phosphate, produced by the pharmaceutical device of the Paris Open public Hospital Authority and certified from EUSA Pharma SAS, may be the initial accepted treatment for LEMS, thereby conferring orphan medication protection and providing a decade of marketplace exclusivity in Europe. It has received orphan medication designation in the U also.S. Related StoriesRaising lupus recognition: an interview with Professor Ramsey-Goldman, MDPhenotyping human illnesses in mice: an interview with Professor Carola Vinuesa’We are thrilled to bring the initial approved therapeutic substitute for the EU to take care of LEMS, a rare, debilitating and serious illness as we increase our commercial portfolio with this fourth approved product,’ said Jean-Jacques Bienaime, CEO of BioMarin.